I期临床-话题@MedSci

#I期临床#

570篇内容 | 7651人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652883, encodeId=503d1652883cf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, objectType=article, longId=163805, objectId=7958163805a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7958163805a9, replyNumber=0, likeNumber=56, createdTime=2019-04-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7958163805a9, moduleTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7958163805a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652847, encodeId=eb98165284e5f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Spago Nanomedical启动I期临床试验SPAGOPIX01, objectType=article, longId=156441, objectId=ef4d156441d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef4d156441d5, replyNumber=0, likeNumber=56, createdTime=2018-12-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef4d156441d5, moduleTitle=Spago Nanomedical启动I期临床试验SPAGOPIX01, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef4d156441d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652837, encodeId=83f1165283e92, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, objectType=article, longId=149146, objectId=06fb149146c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fb149146c6, replyNumber=0, likeNumber=69, createdTime=2018-12-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fb149146c6, moduleTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fb149146c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652839, encodeId=cf5016528391e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=80, createdTime=2019-06-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652853, encodeId=f90d165285348, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Netarsudil眼科解决方案在II期临床中取得积极成果, objectType=article, longId=157813, objectId=d56715e8132b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d56715e8132b, replyNumber=0, likeNumber=65, createdTime=2019-09-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d56715e8132b, moduleTitle=Netarsudil眼科解决方案在II期临床中取得积极成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d56715e8132b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652861, encodeId=fb32165286182, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据, objectType=article, longId=160407, objectId=b51a16040ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b51a16040ede, replyNumber=0, likeNumber=74, createdTime=2019-08-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b51a16040ede, moduleTitle=Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b51a16040ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652854, encodeId=7dba165285445, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=85, createdTime=2019-12-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652827, encodeId=74a3165282e0c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAMA Neurol：α-突触核蛋白单抗PRX002 I期临床结果喜人, objectType=article, longId=141055, objectId=b91214105543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b91214105543, replyNumber=0, likeNumber=71, createdTime=2018-11-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b91214105543, moduleTitle=JAMA Neurol：α-突触核蛋白单抗PRX002 I期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b91214105543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652870, encodeId=b7ae16528e007, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=83, createdTime=2019-06-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652841, encodeId=6f18165284166, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Vedanta生物制药宣布启动炎症性肠病疗法的I期临床研究, objectType=article, longId=154593, objectId=ed5e15459345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed5e15459345, replyNumber=0, likeNumber=68, createdTime=2019-06-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed5e15459345, moduleTitle=Vedanta生物制药宣布启动炎症性肠病疗法的I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed5e15459345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652849, encodeId=d28d1652849c3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著, objectType=article, longId=156635, objectId=3f5e156635a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f5e156635a8, replyNumber=0, likeNumber=101, createdTime=2019-08-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f5e156635a8, moduleTitle=Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f5e156635a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652836, encodeId=5def1652836d3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表, objectType=article, longId=147648, objectId=0b0214e648e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b0214e648e1, replyNumber=0, likeNumber=70, createdTime=2019-01-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b0214e648e1, moduleTitle=Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b0214e648e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652858, encodeId=14531652858c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, objectType=article, longId=159650, objectId=141815965033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141815965033, replyNumber=0, likeNumber=82, createdTime=2019-02-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141815965033, moduleTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=141815965033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652823, encodeId=42bb1652823c1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, objectType=article, longId=135459, objectId=662a13545945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662a13545945, replyNumber=0, likeNumber=61, createdTime=2018-10-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662a13545945, moduleTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662a13545945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652848, encodeId=efc816528483a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=63, createdTime=2019-07-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652821, encodeId=e7211652821e1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究, objectType=article, longId=130890, objectId=c161130890e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c161130890e4, replyNumber=0, likeNumber=73, createdTime=2018-07-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c161130890e4, moduleTitle=EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c161130890e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652850, encodeId=0032165285014, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=0, createdTime=2019-09-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652818, encodeId=37541652818c9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Teva的皮下哮喘药物在III期临床试验中失败, objectType=article, longId=127488, objectId=74dd12e488a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dd12e488a0, replyNumber=0, likeNumber=111, createdTime=2018-03-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dd12e488a0, moduleTitle=Teva的皮下哮喘药物在III期临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74dd12e488a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652828, encodeId=59891652828ab, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=88, createdTime=2018-10-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652819, encodeId=09ce16528197f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Mithra宣布Donesta的II期临床试验已经完成, objectType=article, longId=128113, objectId=70ca12811316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ca12811316, replyNumber=0, likeNumber=80, createdTime=2018-06-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ca12811316, moduleTitle=Mithra宣布Donesta的II期临床试验已经完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ca12811316)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据

2019-04-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Spago Nanomedical启动I期临床试验SPAGOPIX01

2018-12-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景

2018-12-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2019-06-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Netarsudil眼科解决方案在II期临床中取得积极成果

2019-09-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据

2019-08-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-12-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAMA Neurol：α-突触核蛋白单抗PRX002 I期临床结果喜人

2018-11-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2019-06-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Vedanta生物制药宣布启动炎症性肠病疗法的I期临床研究

2019-06-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著

2019-08-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表

2019-01-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤

2019-02-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

PLOS ONE：天花疫苗MVA的III期临床试验结果

2018-10-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2019-07-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究

2018-07-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Incyte宣布开展Ruxolitinib的III期临床试验

2019-09-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Teva的皮下哮喘药物在III期临床试验中失败

2018-03-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-10-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Mithra宣布Donesta的II期临床试验已经完成

2018-06-08

科室
- - 订阅+
  - 更多科室
工具
服务